Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Cambritaxestat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Cambritaxestat: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
XSTEM Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
XSTEM: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Benserazide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Benserazide: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Cilengitide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Cilengitide: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PT-20 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
PT-20: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SN38-SPL9111 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
SN38-SPL9111: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SPL84-23-1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
SPL84-23-1: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SEA-CD40 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
SEA-CD40: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
WVE-N531 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
WVE-N531: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BTX-A51 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
BTX-A51: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CBT-1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
CBT-1: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SJ-557733 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
SJ-557733: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.